Landmarks in prostate cancer diagnosis: the biomarkers

Authors


Professor Walter Artibani, Department of Urology, University of Verona, Policlinico Borgo Roma, P.le L.A. Scuro 10, 37135 Verona, Italy. e-mail: walter.artibani@univr.it

Abstract

  • • The main diagnostic biomarker in current use is prostate-specific antigen (PSA) and it is one of the recommended diagnostic tools from the European Association of Urology Guidelines on prostate cancer.
  • • One of the challenges with PSA is that men with very low levels of PSA can harbour prostate cancer, making it difficult to set a lower limit.
  • • Several modifications to PSA biomarker detection have been suggested to improve its sensitivity and selectivity including PSA density, free:total PSA, PSA velocity/doubling time and different PSA isoforms.
  • • However, there remains a need to improve accuracy of diagnosis and this has led to research in to a number of promising new biomarkers.
  • • These include genetic and blood or urine based biomarkers. The most advanced of these is prostate cancer gene 3 found in urine and developed into a commercial test in 2006.
  • • Other promising markers include circulating tumour cells (CTC) in blood, which have been correlated with survival in castration-resistant prostate cancer. A system for evaluating CTC was approved by the USA Food and Drug Administration in 2008.

Ancillary